Why the study?
Does a single dose of BNT162b2 mRNA vaccine elicit similar antibody responses in individuals with prior SARS-CoV-2 infection compared to two doses in those without prior infection?
Does a single dose of BNT162b2 mRNA vaccine elicit similar antibody responses in individuals with prior SARS-CoV-2 infection compared to two doses in those without prior infection?
A single dose of the BNT162b2 mRNA vaccine in previously infected individuals elicits a similar antibody response to two doses in uninfected individuals.
This is the authors' abstract. We don't add key points for this paper.
In a cohort of BNT162b2 (Pfizer-BioNTech) mRNA vaccine recipients (n = 1,090), we observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition responses elicited by a single vaccine dose in individuals with prior SARS-CoV-2 infection (n = 35) were similar to those seen after two doses of vaccine in individuals without prior infection (n = 228). Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose.
May support single-dose BNT162b2 in previously infected; leaves open clinical protection equivalence versus two doses in naive individuals.
No takes yet. Share an insight, caveat, or question.
Ebinger et al. (2021) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: